Violet 29 is under risk evaluation review by the EPA as part of the
Toxic Substances Control Act (TSCA). In early 2021, the EPA Final Risk Review found "no unreasonable risk" to the environment, consumers, bystanders, or the general population for any conditions of use for Violet 29. However, the EPA found an "unreasonable risk" to workers from the domestic manufacturing or import of the chemical and nearly all uses and disposal. This finding under the TSCA is for alveolar hyperplasia, inflammatory and morphological changes in the
lower respiratory tract for chronic inhalation exposures. The finding of "unreasonable risk" requires the EPA to work to reduce or manage the risk, including banning the use of a particular chemical. == References ==